Top

Journal of Mammary Gland Biology and Neoplasia

Published in:

01-03-2009

Treatment Resistance in Stem Cells and Breast Cancer

Authors: Bhuvanesh Dave, Jenny Chang

Published in: Journal of Mammary Gland Biology and Neoplasia | Issue 1/2009

Abstract

Cancer stem cells are resistant to current chemotherapy and radiation regimens available for breast cancer, making it imperative to study the mechanisms of resistance and development of therapeutic strategies that targets the tumor initiating cell population. One of the difficulties in identifying new drug targets has been that our current high throughput drug screens look for tumor shrinkage and do not incorporate the impact of compounds on the cancer stem cell population. In this review we discuss the literature on treatment resistance in breast cancer and the design of new clinical trials for test compounds which will allow us to determine both the reduction in tumor size and decrease in cancer stem cell population. In order to detect the effect of target compounds on cancer stem cells in a clinical setting, we will need to do multiple assays which include high throughput flow sorting analysis to determine the total number of CD44⁺/CD24^−/low/Lin⁻ and ALDH1 positive cells, as well as in-vitro mammosphere formation assay which is a functional assay dependent on the self renewal and anchorage independent growth properties of these cells.

Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194(4260):23–8. doi:10.1126/science.959840.PubMedCrossRef

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57–70. doi:10.1016/S0092-8674(00)81683-9.PubMedCrossRef

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100(7):3983–8. doi:10.1073/pnas.0530291100.PubMedCrossRef

Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65(13):5506–11. doi:10.1158/0008-5472.CAN-05-0626.PubMedCrossRef

Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005;23(6):1169–77. doi:10.1200/JCO.2005.03.156.PubMedCrossRef

Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100(9):672–9. doi:10.1093/jnci/djn123.PubMedCrossRef

Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131(6):1109–23. doi:10.1016/j.cell.2007.10.054.PubMedCrossRef

Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007;43(5):867–76. doi:10.1016/j.ejca.2006.12.009.PubMedCrossRef

Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1(5):555–67. doi:10.1016/j.stem.2007.08.014.PubMedCrossRef

10.

Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008;10(3):R53. doi:10.1186/bcr2108.PubMedCrossRef

11.

Krop IE, Kosh M, Fearen I, Savoie J, Dallob A, Matthews C, Stone J, Winer E, Freedman SJ, Lorusso P. Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. Journal of Clinical Oncology, 2006 ASCO Annual Meeting. Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 10574.

12.

LoRusso PM, Rudin CM, Borad MJ, Vernillet L, Darbonne WC, Mackey H, DiMartino JF, de Sauvage F, Low JA, Von Hoff DD. A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors. J Clin Oncol 26: 2008 (May 20 suppl; abstr 3516.

Title: Treatment Resistance in Stem Cells and Breast Cancer
Authors: Bhuvanesh Dave
Jenny Chang
Publication date: 01-03-2009
Publisher: Springer US
Published in: Journal of Mammary Gland Biology and Neoplasia / Issue 1/2009
Print ISSN: 1083-3021
Electronic ISSN: 1573-7039
DOI: https://doi.org/10.1007/s10911-009-9117-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Hormone-Induced Protection Against Breast Cancer

Stemming Resistance to HER-2 Targeted Therapy

Resistance to Endocrine Therapy: Are Breast Cancer Stem Cells the Culprits?

ABC Transporters, Drug Resistance, and Cancer Stem Cells

ER Re-expression and Re-sensitization to Endocrine Therapies in ER-negative Breast Cancers

Tumor-Initiating Cells and Treatment Resistance: How Goes the War?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer